Skip to main content
    V

    VistaGen Therapeutics Inc (VTGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.18
    +0.00 (+2.11%)

    Market Cap: $8.01M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    VistaGen Therapeutics Inc (VTGN) Financials: Revenue, Profit and Cash Flow

    Updated Nov 13, 2026. Financial statements from company filings, amounts in US dollars.

    VistaGen Therapeutics reported revenue of $1.27M for the fiscal year ended Mar 31, 2026, up 161.1% from the year before. That year, net income was -$69.69M with a net margin of -5491.3%, operating cash flow was -$66.44M and free cash flow was -$66.59M. The quarter ended Sep 30, 2026 had revenue of $138.00K and net income of -$10.74M.

    Revenue and Margins

    Over the 9 years to Mar 2026, revenue grew from $1.25M, a compound annual rate of 0.2%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Mar 2026$1.27M+161.1%100.0%-5683.7%-5491.3%
    Mar 2025$486.00K-54.3%100.0%-11517.1%-10579.8%
    Mar 2024$1.06MN/A100.0%-3103.5%-2759.6%
    Mar 2023$0-100.0%N/AN/AN/A
    Mar 2022$1.11M+1.8%100.0%-4308.7%-4307.2%
    Mar 2021$1.09MN/A100.0%-1646.1%-1646.1%
    Mar 2020$0N/AN/AN/AN/A
    Mar 2019$0N/AN/AN/AN/A
    Mar 2018$0-100.0%N/AN/AN/A
    Mar 2017$1.25MN/A100.0%-819.9%-820.4%
    Annual, fiscal years ended Mar 2017 to Mar 2026

    Income Statement

    In the fiscal year ended Mar 2026, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Revenue$1.27M$486.00K$1.06M$0$1.11M$1.09M$0$0$0$1.25M
    Gross profit$1.27M$486.00K$1.06M$0$1.11M$1.09M$0$0$0$1.25M
    Research and development$54.97M$39.38M$20.02M$44.38M$35.41M$11.93M$13.37M$17.10M$7.76M$5.20M
    Operating income-$72.13M-$55.97M-$33.02M-$59.27M-$47.78M-$17.93M-$20.80M-$24.56M-$14.20M-$10.25M
    Net income-$69.69M-$51.42M-$29.36M-$59.25M-$47.76M-$17.93M-$20.77M-$24.59M-$14.35M-$10.26M
    EBITDA-$71.39M-$55.33M-$32.14M-$58.74M-$47.07M-$17.46M-$20.68M-$24.35M-$13.97M-$10.11M
    Fiscal years ended Mar 2017 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$138.00K$1.48M$464.00K$303.00K$258.00K$244.00K-$15.00K$234.00K$183.00K$84.00K$198.00K$411.00K
    Gross profit$138.00K$1.48M$464.00K$303.00K$258.00K$244.00K-$15.00K$234.00K$183.00K$84.00K$198.00K$411.00K
    Operating income-$10.94M-$13.35M-$16.72M-$19.55M-$20.05M-$15.80M-$14.49M-$15.12M-$14.23M-$12.13M-$11.36M-$7.88M
    Net income-$10.74M-$13.03M-$16.27M-$18.90M-$19.42M-$15.10M-$13.63M-$14.09M-$12.96M-$10.73M-$9.52M-$6.35M
    Last 12 quarters

    Balance Sheet

    As of Mar 2026, cash and equivalents exceeded total debt of $192.00K by $30.60M.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Total assets$48.56M$84.34M$123.65M$21.09M$74.64M$108.28M$5.77M$14.01M$11.28M$3.71M
    Current assets$46.94M$82.08M$120.67M$17.51M$71.00M$104.12M$1.58M$13.63M$11.02M$3.38M
    Cash and equivalents$30.79M$67.13M$119.17M$16.64M$68.14M$103.11M$1.36M$13.10M$10.38M$2.92M
    Total liabilities$13.04M$13.95M$9.37M$9.01M$9.93M$16.30M$11.50M$6.94M$4.36M$3.10M
    Short-term debt$96.00K$561.00K$550.00K$105.00K$0$367.80K$56.50K$57.30K$56.50K$57.20K
    Long-term debt$96.00K$0N/AN/AN/AN/AN/AN/A$9.00K$12.00K
    Shareholder equity$35.52M$70.39M$114.29M$12.08M$64.72M$91.98M-$5.73M$7.08M$6.91M$619.80K
    Fiscal years ended Mar 2017 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$23.42M$35.74M$48.56M$65.06M$80.93M$68.92M$84.34M$92.31M$102.50M$113.55M$123.65M$131.07M
    Total liabilities$8.43M$11.26M$13.04M$14.14M$14.59M$12.16M$13.95M$11.19M$9.52M$8.74M$9.37M$7.78M
    Cash and equivalents$10.89M$16.99M$30.79M$47.37M$62.79M$48.98M$67.13M$74.72M$84.25M$102.92M$119.17M$126.56M
    Shareholder equity$14.99M$24.48M$35.52M$50.92M$66.34M$56.77M$70.39M$81.12M$92.97M$104.80M$114.29M$123.28M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Mar 2026.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Operating cash flow-$66.44M-$42.10M-$25.81M-$49.72M-$45.26M-$12.07M-$15.76M-$14.53M-$9.06M-$7.26M
    Capital expenditures$151.00K$191.00K$61.00K$528.00K$0$275.40K$0$174.00K$1.60K$239.10K
    Free cash flow-$66.59M-$42.29M-$25.87M-$50.24M-$45.26M-$12.35M-$15.76M-$14.70M-$9.06M-$7.50M
    Dividends paidN/AN/AN/A$866.96M$945.10M$1.39B$1.26B$1.14B$1.03B$1.26B
    Investing cash flow-$877.00K-$13.15M-$61.00K-$740.00K-$200.40K-$275.40K$0-$174.00K-$1.60K-$239.10K
    Financing cash flow$30.97M$3.21M$128.40M-$1.04M$10.48M$114.10M$4.01M$17.42M$16.52M$9.99M
    Fiscal years ended Mar 2017 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$12.16M-$14.71M-$16.20M-$17.63M-$13.76M-$18.85M-$10.06M-$10.28M-$10.89M-$10.87M-$6.99M-$4.75M
    Capital expendituresN/A$0$125.00K$26.00K$60.00K$65.00K$88.00K$0$61.00K$42.00K$28.70K$32.00K
    Free cash flowN/A-$14.71M-$16.32M-$17.66M-$13.82M-$18.91M-$10.15M-$10.28M-$10.95M-$10.91M-$7.01M-$4.78M
    Last 12 quarters

    Frequently Asked Questions About VTGN

    What is VistaGen Therapeutics' annual revenue?

    VistaGen Therapeutics reported revenue of $1.27M for the fiscal year ended Mar 31, 2026.

    How fast is VistaGen Therapeutics' revenue growing?

    Revenue was up 161.1% for the fiscal year ended Mar 31, 2026 compared with the year before.

    Is VistaGen Therapeutics profitable?

    No. VistaGen Therapeutics reported net income of -$69.69M for the fiscal year ended Mar 31, 2026, with a net margin of -5491.3%.

    How much free cash flow does VTGN generate?

    For the fiscal year ended Mar 31, 2026, operating cash flow of -$66.44M minus capital expenditures of $151.00K produced free cash flow of -$66.59M.

    How much debt does VistaGen Therapeutics have?

    The balance sheet dated Mar 31, 2026 reported long-term debt of $96.00K, short-term debt of $96.00K and cash and equivalents of $30.79M.